Comparison · NCT05306873-36ddeea4
Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Incidence of Grade 3 or Higher Hypertension in Stage 3
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Stage 3 MMF + Voclosporin vs Stage 3 MMF + Placebo for Voclosporin: The Incidence of Grade 3 or Higher Hypertension in Stage 3. Trial comparisons, record NCT05306873-36ddeea4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05306873-36ddeea4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.658 | wilson | |
| Risk in group 2 | 0 | 0 | 0.793 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.793 | 0.658 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Stage 3 MMF + Voclosporin | Participants receive up to 24 weeks MMF plus 23.7 mg voclosporin (3 x 7.9 mg capsules) twice daily. Participants who previously received placebo in Stage 2 receive a scheduled ramp-up of MMF for the first two weeks.~Participants who received placebo in Stage 2:~* Week 1: participants receive 500 mg MMF plus matching MMF placebo (to appear like a 1000mg dose) twice daily~* Week 2: participants receive 500 mg plus matching placebo for MMF (to appear like a 1000 mg dose) and 1000 mg MMF in divided doses~* Weeks 3-24: 1000 mg MMF twice daily~Participants who receive MMF in Stage 2:~• Weeks 1-24: 1000 mg MMF twice daily | 0 | 2 | OG000 |
| Group 2 | Stage 3 MMF + Placebo for Voclosporin | Participants receive up to 24 weeks MMF plus 23.7 mg voclosporin placebo (3 x 7.9 mg capsules) twice daily. Participants who previously received placebo in Stage 2 receive a scheduled ramp-up of MMF for the first two weeks.~Participants who received placebo in Stage 2:~* Week 1: participants receive 500 mg MMF plus matching MMF placebo (to appear like a 1000mg dose) twice daily~* Week 2: participants receive 500 mg plus matching placebo for MMF (to appear like a 1000 mg dose) and 1000 mg MMF in divided doses~* Weeks 3-24: 1000 mg MMF twice daily~Participants who received MMF in Stage 2:~• Weeks 1-24: 1000 mg MMF twice daily | 0 | 1 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Incidence of Grade 3 or Higher Hypertension in Stage 3
- Description
- Defined as a systolic blood pressure \>= 160 mm Hg or a diastolic blood pressure of \>= 100 mm Hg
- Time frame
- After Stage 3 re-randomization Day 0 to Stage 3 Week 24
- Population
- Includes participants who received at least one dose Stage 3 study drug.
Source ClinicalTrials.gov
Trial
- Title
- Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
- NCT number
- NCT05306873
- Phases
- PHASE2
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin, Mycophenolate Mofetil
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2025-09-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05306873?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05306873-36ddeea4